Document is current
Any future updates will be listed below
-
Authors
de Jonge, A. Vera https://orcid.org/0000-0002-5397-1762
van Werkhoven, Erik https://orcid.org/0000-0001-7469-7427
Dinmohamed, Avinash G. https://orcid.org/0000-0002-4767-6716
Nijland, Marcel
Zwinderman, Aeilko H.
Bossuyt, Patrick M.
Veldhuis, Martine S.
Rutten, Emma G. G. M.
Mous, Rogier
Vermaat, Joost S. P. https://orcid.org/0000-0002-1628-6256
Sandberg, Yorick
de Jongh, Eva
Bilgin, Yavuz M.
Boersma, Rinske
Koene, Harry
Kersten, Marie José
de Jong, Daphne https://orcid.org/0000-0002-9725-4060
Chamuleau, Martine E. D. https://orcid.org/0000-0002-0123-9182
-
Funding
Funding for this research was provided by:
Genmab (consultancy), Takeda (research funding), Roche
BMS/Celgene, Kite, Roche (honoraria and research funding) Miltenyi Biotech, Novartis, Takeda, Adicet Bio
KWF Kankerbestrijding (VUMC 2013-6269, EMCR 2014-7436)
BMS/Celgene (Honoraria and research funding), Gilead and Genmab (research funding), Roche, Abbvie, Novartis
- License Information
-
More Information
Article History
Received: 27 January 2023
Revised: 25 April 2023
Accepted: 3 May 2023
First Online: 22 May 2023
Competing interests
: AVDJ, EVW, AGD, MN, AHZ, PMB, MSV, EGGMR, RM, JSPV, YS, EDJ, YM, RB, HK, and DDJ declare no competing financial interests. MJK received honoraria from Kite, Novartis, and Miltenyi Biotech, Roche, and Bristol Myers Squibb/Celgene; consultancy or advisory role for Kite, Roche, Bristol Myers Squibb/Celgene, Novartis, and Miltenyi Biotech; research funding from Kite, Roche, Takeda, and Celgene (all to institution); and travel support from Kite, Roche, Novartis, and Miltenyi Biotech. MEDC received research funding from BMS/Celgene, Gilead and GenMAb. Advisory role for AbbVie and Novartis.
